Ferguson GT - Search Results

1

Why does the lung hyperinflate?

Ferguson GT. Ferguson GT. Proc Am Thorac Soc. 2006 Apr;3(2):176-9. doi: 10.1513/pats.200508-094DO. Proc Am Thorac Soc. 2006. PMID: 16565428 Review.

2

Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education Program.

Ferguson GT, Enright PL, Buist AS, Higgins MW. Ferguson GT, et al. Respir Care. 2000 May;45(5):513-30. Respir Care. 2000. PMID: 10813228 Review.

3

Cardiovascular safety of salmeterol in COPD.

Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Ferguson GT, et al. Chest. 2003 Jun;123(6):1817-24. doi: 10.1378/chest.123.6.1817. Chest. 2003. PMID: 12796155 Clinical Trial.

4

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.

Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Celli BR, et al. Among authors: ferguson gt. Am J Respir Crit Care Med. 2008 Aug 15;178(4):332-8. doi: 10.1164/rccm.200712-1869OC. Epub 2008 May 29. Am J Respir Crit Care Med. 2008. PMID: 18511702 Clinical Trial.

5

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.

Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Ferguson GT, et al. Respir Med. 2008 Aug;102(8):1099-108. doi: 10.1016/j.rmed.2008.04.019. Epub 2008 Jul 9. Respir Med. 2008. PMID: 18614347 Clinical Trial.

6

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.

Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J. Crim C, et al. Among authors: ferguson gt. Eur Respir J. 2009 Sep;34(3):641-7. doi: 10.1183/09031936.00193908. Epub 2009 May 14. Eur Respir J. 2009. PMID: 19443528 Clinical Trial.

7

Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study.

Ferguson GT, Calverley PMA, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B. Ferguson GT, et al. Chest. 2009 Dec;136(6):1456-1465. doi: 10.1378/chest.08-3016. Epub 2009 Jul 6. Chest. 2009. PMID: 19581353 Clinical Trial.

8

Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience.

Celli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT, Calverley PM, Yates JC, Anderson JA, Willits LR, Wise RA; Investigators of the TORCH Study. Celli B, et al. Among authors: ferguson gt. Am J Respir Crit Care Med. 2011 Feb 1;183(3):317-22. doi: 10.1164/rccm.201004-0665OC. Epub 2010 Sep 2. Am J Respir Crit Care Med. 2011. PMID: 20813884 Clinical Trial.

9

Maintenance pharmacotherapy of mild and moderate COPD: what is the evidence?

Ferguson GT. Ferguson GT. Respir Med. 2011 Sep;105(9):1268-74. doi: 10.1016/j.rmed.2011.02.005. Epub 2011 Feb 25. Respir Med. 2011. PMID: 21353516 Review.

10

COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study.

Ferguson GT, Ghafouri M, Dai L, Dunn LJ. Ferguson GT, et al. Int J Chron Obstruct Pulmon Dis. 2013;8:139-50. doi: 10.2147/COPD.S38577. Epub 2013 Mar 19. Int J Chron Obstruct Pulmon Dis. 2013. PMID: 23658479 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results